贝尔氏麻痹(特发性面神经麻痹)的抗病毒治疗。
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
作者信息
Gagyor Ildiko, Madhok Vishnu B, Daly Fergus, Somasundara Dhruvashree, Sullivan Michael, Gammie Fiona, Sullivan Frank
机构信息
Department of General Practice/Family Medicine, University of Göttingen, Humboldtalle 38, Göttingen, Lower Saxony, Germany, 37073.
出版信息
Cochrane Database Syst Rev. 2015 Nov 9(11):CD001869. doi: 10.1002/14651858.CD001869.pub8.
BACKGROUND
Corticosteroids are widely used in the treatment of idiopathic facial paralysis (Bell's palsy), but the effectiveness of additional treatment with an antiviral agent is uncertain. Significant morbidity can be associated with severe cases of Bell's palsy. This review was first published in 2001 and revised several times, most recently in 2009. This version replaces an update of the review in Issue 7 of the Cochrane Library subsequently withdrawn because of an ongoing investigation into the reliability of data from an included study.
OBJECTIVES
To assess the effects of antiviral treatments alone or in combination with any other therapy for Bell's palsy.
SEARCH METHODS
On 7 October 2014 we searched the Cochrane Neuromuscular Disease Group Specialized Register, CENTRAL, MEDLINE, EMBASE, LILACS, DARE, NHS EED, and HTA. We also reviewed the bibliographies of the identified trials and contacted trial authors and known experts in the field and relevant drug companies to identify additional published or unpublished data. We searched clinical trials registries for ongoing studies.
SELECTION CRITERIA
We considered randomised controlled trials or quasi-randomised controlled trials of antivirals with and without corticosteroids versus control therapies for the treatment of Bell's palsy. We excluded trials that had a high risk of bias in several domains.
DATA COLLECTION AND ANALYSIS
Pairs of authors independently assessed trials for relevance, eligibility, and risk of bias, using standard Cochrane procedures.
MAIN RESULTS
Ten trials, including 2280 participants, met the inclusion criteria and are included in the final analysis. Some of the trials were small, and a number were at high or unclear risk of bias. Other trials did not meet current best standards in allocation concealment and blinding. Incomplete recoveryWe found a significant benefit from adding antivirals to corticosteroids in comparison with corticosteroids alone for people with Bell's palsy (risk ratio (RR) 0.61, 95% confidence interval (CI) 0.39 to 0.97, n = 1315). For people with severe Bell's palsy (House-Brackmann scores of 5 and 6 or the equivalent in other scales), we found a reduction in the rate of incomplete recovery at month six when antivirals plus corticosteroids were used, compared to corticosteroids alone (RR 0.64, 95% CI 0.41 to 0.99, n = 478). The outcome for the participants receiving corticosteroids alone was significantly better than for those receiving antivirals alone (RR 2.82, 95% CI 1.09 to 7.32, n = 768). The treatment effect of placebo was significantly lower than that of antivirals plus corticosteroids (RR 0.56, 95% CI 0.41 to 0.76, n = 658). Antivirals alone produced no benefit compared with placebo (RR 1.10, 95% CI 0.87 to 1.40, n = 658). Motor synkinesis or crocodile tearsIn two trials comparing antivirals and corticosteroids with corticosteroids and placebo that assessed this outcome, we found a significant difference in long-term sequelae in favour of antivirals plus corticosteroids (RR 0.56, 95% CI 0.36 to 0.87, n = 469). Two trials comparing antivirals alone with corticosteroids alone investigating this outcome showed fewer sequelae with corticosteroids (RR 1.52, 95% CI 1.08 to 2.12, n = 472). We found no data on long-term sequelae for other comparisons. Adverse events Adverse event data were available in three studies giving comparison data on 1528 participants. None of the four comparisons (antivirals plus corticosteroids versus corticosteroids plus placebo or no treatment; antivirals versus corticosteroids; antivirals plus corticosteroids versus placebo; antivirals versus placebo) showed significant differences in adverse events between treatment and control arms. We could find no correlation with specific treatment within these results.
AUTHORS' CONCLUSIONS: Low-quality evidence from randomised controlled trials showed a benefit from the combination of antivirals with corticosteroids compared to corticosteroids alone for the treatment of Bell's palsy of various degrees of severity. Low-quality evidence showed a benefit of combination therapy compared with corticosteroids alone in severe Bell's palsy. Corticosteroids alone were more effective than antivirals alone and antivirals plus corticosteroids were more effective than placebo or no treatment. There was no benefit from antivirals alone over placebo.Moderate-quality evidence indicated that the combination of antivirals and corticosteroids reduced sequelae of Bell's palsy compared with corticosteroids alone.We found no significant increase in adverse events from the use of antivirals compared with either placebo or corticosteroids, based on low-quality evidence.
背景
皮质类固醇广泛用于治疗特发性面神经麻痹(贝尔氏麻痹),但联合使用抗病毒药物进行治疗的有效性尚不确定。严重的贝尔氏麻痹病例可能会导致显著的发病率。本综述首次发表于2001年,并多次修订,最近一次修订是在2009年。本版本取代了《Cochrane图书馆》第7期中该综述的更新版,该更新版随后因对一项纳入研究的数据可靠性进行的正在进行的调查而撤回。
目的
评估单独使用抗病毒治疗或与其他任何疗法联合用于贝尔氏麻痹的效果。
检索方法
2014年10月7日,我们检索了Cochrane神经肌肉疾病组专业注册库、Cochrane系统评价数据库、医学期刊数据库、荷兰医学文摘数据库、拉丁美洲及加勒比地区健康科学数据库、循证医学数据库、英国国家卫生服务经济评价数据库和卫生技术评估数据库。我们还查阅了已识别试验的参考文献,并联系了试验作者、该领域的知名专家以及相关制药公司,以识别其他已发表或未发表的数据。我们检索了临床试验注册库以查找正在进行的研究。
入选标准
我们纳入了比较使用或不使用皮质类固醇的抗病毒药物与对照疗法治疗贝尔氏麻痹的随机对照试验或半随机对照试验。我们排除了在多个领域存在高偏倚风险的试验。
数据收集与分析
两位作者独立评估试验的相关性、合格性和偏倚风险,采用Cochrane标准程序。
主要结果
10项试验(包括2280名参与者)符合纳入标准并纳入最终分析。其中一些试验规模较小,许多试验存在高偏倚风险或偏倚风险不明确。其他试验在分配隐藏和盲法方面未达到当前最佳标准。
不完全恢复
我们发现,与单独使用皮质类固醇相比,在皮质类固醇基础上加用抗病毒药物对贝尔氏麻痹患者有显著益处(风险比(RR)0.61,95%置信区间(CI)0.39至0.97,n = 1315)。对于重度贝尔氏麻痹患者(House-Brackmann评分为5和6或其他量表中的等效评分),我们发现,与单独使用皮质类固醇相比,使用抗病毒药物加皮质类固醇在第6个月时不完全恢复率有所降低(RR 0.64,95%CI 0.41至0.99,n = 478)。单独接受皮质类固醇治疗的参与者的结果明显优于单独接受抗病毒药物治疗的参与者(RR 2.82,95%CI 1.09至7.32,n = 768)。安慰剂的治疗效果明显低于抗病毒药物加皮质类固醇(RR 0.56,95%CI 0.41至0.76,n = 658)。与安慰剂相比,单独使用抗病毒药物没有益处(RR 1.10,95%CI 0.87至1.40,n = 658)。
运动联带运动或鳄鱼泪
在两项比较抗病毒药物和皮质类固醇与皮质类固醇和安慰剂并评估此结果的试验中,我们发现长期后遗症存在显著差异,支持抗病毒药物加皮质类固醇(RR 0.56,95%CI 0.36至0.87,n = 469)。两项比较单独使用抗病毒药物与单独使用皮质类固醇并调查此结果的试验显示,皮质类固醇的后遗症较少(RR 1.52,95%CI 1.08至2.12,n = 472)。我们未找到其他比较的长期后遗症数据。
不良事件
三项研究提供了1528名参与者的不良事件比较数据。四项比较(抗病毒药物加皮质类固醇与皮质类固醇加安慰剂或不治疗;抗病毒药物与皮质类固醇;抗病毒药物加皮质类固醇与安慰剂;抗病毒药物与安慰剂)均未显示治疗组和对照组之间在不良事件方面存在显著差异。在这些结果中,我们未发现与特定治疗的相关性。
作者结论
随机对照试验的低质量证据表明,与单独使用皮质类固醇相比,抗病毒药物与皮质类固醇联合使用对治疗各种严重程度的贝尔氏麻痹有益。低质量证据表明,联合治疗对重度贝尔氏麻痹患者比单独使用皮质类固醇有益。单独使用皮质类固醇比单独使用抗病毒药物更有效,抗病毒药物加皮质类固醇比安慰剂或不治疗更有效。单独使用抗病毒药物与安慰剂相比没有益处。中等质量证据表明,与单独使用皮质类固醇相比,抗病毒药物和皮质类固醇联合使用可减少贝尔氏麻痹的后遗症。基于低质量证据,我们发现与安慰剂或皮质类固醇相比,使用抗病毒药物并未显著增加不良事件。